GuidelineThe journal of headache and pain2018
Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation.
Guideline in The journal of headache and pain, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials.The journal of headache and pain · 2020Pooled it
- Exploring the epigenetic modifications of the RONS-TRPA1-CGRP axis in migraine pathophysiology.The journal of headache and pain · 2025Review
- Effect of lacosamide on cortical spreading depolarization in mice.The journal of headache and pain · 2025Article
- Current Trends in Pediatric Migraine: Clinical Insights and Therapeutic Strategies.Brain sciences · 2025Review
- Health equity, care access and quality in headache - part 2.The journal of headache and pain · 2023Review
- Valproate pregnancy prevention scheme: what are the barriers to enrolling patients and how do we meet them?BMJ neurology open · 2023Article
- Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study.The journal of headache and pain · 2022Article
- Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study.BMC pregnancy and childbirth · 2022Article
- Pediatric Headache in Primary Care and Emergency Departments: Consensus with RAND/UCLA Method.Life (Basel, Switzerland) · 2022Article
- Management of Chronic Migraine in Children and Adolescents: Where are We in 2022?Pediatric health, medicine and therapeutics · 2022Review
- Nutrients to Improve Mitochondrial Function to Reduce Brain Energy Deficit and Oxidative Stress in Migraine.Nutrients · 2021Review
- Headache in people with epilepsy.Nature reviews. Neurology · 2021Review
- Diagnosis and management of migraine in ten steps.Nature reviews. Neurology · 2021Review
- Article
- Article
- Real world preventative drug management of migraine among Spanish neurologists.The journal of headache and pain · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a common and burdensome neurological condition which affects mainly female patients during their childbearing years. Valproate has been widely used for the prophylaxis of migraine attacks and is also included in the main European Guidelines. Previous (2014) European recommendations on limiting the use of valproate in women of childbearing age did not achieve their objective in terms of limiting the use of valproate in women of childbearing age and raising awareness regarding the hazardous effect of valproate to children exposed in utero. The teratogenic and foetotoxic effects of valproate are well documented, and more recent studies show that there is an even greater neurodevelopmental risk to children exposed to valproate in the womb. The latest 2018 European review from the European Medicines Agency, with the active participation of the European Headache Federation, concluded that not enough has been done to mitigate the risks associated with in utero exposure to valproate. The review called for more extensive restrictions to the conditions for prescribing, better public awareness, and a more effective education campaign in migrainous women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.